DPX-0907, an experimental therapeutic cancer vaccine by Immunovaccine Inc., has entered the first in man human studies, a crucial stage in drug development.
DPX-0907, which could offer cover for breast, ovarian, and prostate cancers has been cleared by the US Food and Drug Administration for the phase 1 human studies, said Immunovaccine Inc. in a press statement.
DPX-0907 is designed to cause a depot effect that has the potential to stimulate the body’s immune system to seek out and destroy cancer cells in patients with breast, ovarian and prostate cancer.
DPX-0907 is Immunovaccine’s lead therapeutic vaccine candidate and uses the DepoVax platform to deliver tumor specific antigens.
“DPX-0907 is an appealing vaccine candidate to advance into human clinical trials because it combines the strength of our DepoVax platform with cancer signature antigens,” stated Dr Randal Chase, Immunovaccine’s president and CEO.
The Phase 1 clinical trial for DPX-0907 will be conducted at five sites in the US and is on track to begin enrolling patients with breast, ovarian, and prostate cancers by the end of Q1 2010.
The Phase 1 clinical trial will evaluate the safety and tolerability of Immunovaccine’s patented DepoVax delivery system and seven tumor-associated antigens.
DPX-0907 vaccine produced a specific cellular immune response that was superior to immune responses achieved with other oil depot vaccines in preclinical models, Immunovaccine said.
DPX-0907 does not induce regulatory T-cell immune suppression, therefore enabling a longer lasting anti-tumor immune response, preclinical research revealed.
The DepoVax delivery platform used to formulate DPX-0907 was capable of achieving 100% therapeutic tumor elimination using established preclinical models.
Therapeutic cancer vaccines represent one of the most promising and rapidly advancing frontiers in drug discovery.
DepoVax, Immunovaccine’s patented vaccine delivery system, has strong preclinical data that has shown it to be a safe and effective way to deliver antigens. The DepoVax platform is protected by a strong portfolio of issued patents and pending patent applications.
Immunovaccine Inc is headquartered at Halifax, Nova Scotia.
In November, Immunovaccine Inc signed an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine’s patented vaccine delivery technology. Under the terms of the agreement, which were not disclosed, Immunovaccine will receive upfront signing fees in
addition to subsequent milestone payments and royalties on any Immunovaccine-delivered vaccines developed by Pfizer Animal Health.